You are here

  • Home
  • Archive
  • Volume 13, Issue 3
  • Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine/naloxone for the treatment of opioid use disorder using a microdosing approach

Article info

Article menu
Download PDFPDF
Innovations in Treatment
Case report
Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine/naloxone for the treatment of opioid use disorder using a microdosing approach

Authors

  1. Correspondence to Dr Seonaid Nolan; bccsu-sn{at}bccsu.ubc.ca
View Full Text

Citation

Caulfield MDG, Brar R, Sutherland C, et al
Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine/naloxone for the treatment of opioid use disorder using a microdosing approach
BMJ Case Reports CP 2020;13:e233715.

Publication history

  • Accepted March 10, 2020
  • First published March 25, 2020.
Online issue publication 
March 25, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.